Genetic migraine disorders and the response to calcitonin gene‐related peptide antagonist treatment

Documenti analoghi

• Evaluating dual calcitonin gene‐related peptide antagonists for chronic migraine prevention
  di: Kara S. Graves, et al.
  Pubblicazione: (2026)
• Treatment of abdominal migraine in an 8‐year‐old child with calcitonin gene‐related peptide receptor antagonist: A case report
  di: Yunzhu Tang, et al.
  Pubblicazione: (2025)
• Patient reported outcomes and the real‐world use of calcitonin gene–related peptide medications in migraine
  di: Samuel K. Peasah, et al.
  Pubblicazione: (2024)
• Potential drug interaction between calcitonin gene‐related peptide antagonists and neonatal Fc receptor inhibitors
  di: Alex Harlan, et al.
  Pubblicazione: (2025)
• Persistence, effectiveness, and tolerability of anti‐calcitonin gene–related peptide monoclonal antibodies in patients with chronic migraine
  di: Anna de Dios, et al.
  Pubblicazione: (2024)